Giangiacomi Francesco, Faggiano Andrea, Cardinale Daniela, Rossi Francesca Gaia, Pollina Alberto, Gherbesi Elisa, Gnan Eleonora, Carugo Stefano, Vicenzi Marco
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Dyspnea Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Front Cardiovasc Med. 2023 Aug 22;10:1250185. doi: 10.3389/fcvm.2023.1250185. eCollection 2023.
To describe the efficacy and safety of sodium-glucose cotransporter 2 inhibitors as a specific treatment for anthracycline-related cardiac dysfunction in a small real-world population.
Seven patients with anthracycline-related cardiac dysfunction were clinically and echocardiographically evaluated before and after the introduction of sodium-glucose cotransporter 2 inhibitors.
After a median period of 24 weeks with uninterrupted sodium-glucose cotransporter 2 inhibitors treatment, a significant clinical improvement was observed with at least one New York Heart Association Functional Class (NHYA FC) improvement in all patients (median NYHA FC: I vs. III, < 0.010). A noteworthy left ventricular reserve remodeling (median left ventricular end diastolic volume indexed: 53 vs. 82.5 ml/m, = 0.018; median left ventricular ejection fraction: 50% vs. 40%, = 0.17) was also observed. Sodium-glucose cotransporter 2 inhibitors therapy was well tolerated by every patients; no cases of discontinuation or relevant side effects were observed.
Sodium-glucose cotransporter 2 inhibitors induce a significant clinical improvement and left ventricular reserve remodeling in patients affected by anthracycline-related cardiac dysfunction.
描述钠-葡萄糖协同转运蛋白2抑制剂作为一种针对小样本真实世界人群中蒽环类药物相关心脏功能障碍的特异性治疗方法的疗效和安全性。
对7例蒽环类药物相关心脏功能障碍患者在引入钠-葡萄糖协同转运蛋白2抑制剂前后进行临床和超声心动图评估。
在接受钠-葡萄糖协同转运蛋白2抑制剂不间断治疗的中位时间24周后，观察到显著的临床改善，所有患者的纽约心脏协会心功能分级（NHYA FC）至少改善一级（中位NYHA FC：I级对III级，P<0.010）。还观察到值得注意的左心室储备重构（中位左心室舒张末期容积指数：53对82.5ml/m²，P=0.018；中位左心室射血分数：50%对40%，P=0.17）。所有患者对钠-葡萄糖协同转运蛋白2抑制剂治疗耐受性良好；未观察到停药或相关副作用的病例。
钠-葡萄糖协同转运蛋白2抑制剂可使蒽环类药物相关心脏功能障碍患者的临床症状显著改善，并使左心室储备重构。
